+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Clinical Trials Market in the US 2025-2029

  • PDF Icon

    Report

  • 166 Pages
  • February 2025
  • Region: United States
  • TechNavio
  • ID: 5892866
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The clinical trials market in the US is forecasted to grow by USD 6.5 billion during 2024-2029, accelerating at a CAGR of 5.3% during the forecast period. The report on the clinical trials market in the US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in number of clinical trials of drugs, rise in adoption of artificial intelligence (AI)-based tools for drug delivery, and growing demand for personalized medicine and targeted therapies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

The clinical trials market in the US is segmented as below:

By Type

  • Phase III
  • Phase I
  • Phase II
  • Phase IV

By Service Type

  • Interventional studies
  • Observational studies
  • Expanded access studies

By Indication

  • Oncology
  • CNS
  • Autoimmune/inflammation
  • Others

By Geographical Landscape

  • North America
This study identifies the advancement in technology and scientific research as one of the prime reasons driving the clinical trials market in the US growth during the next few years. Also, rise in outsourcing of clinical trial process and growing investment in healthcare and pharmaceutical industries will lead to sizable demand in the market.

The report on the clinical trials market in the US covers the following areas:

  • Clinical Trials Market in the US sizing
  • Clinical Trials Market in the US forecast
  • Clinical Trials Market in the US industry analysis
A robust vendor analysis within the report is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading clinical trials market in the US vendors that include Accell Clinical Research LLC, Apex Medical Research Inc., Caidya, Charles River Laboratories International Inc., Clario, Clinipace Inc., CTI Clinical Trial and Consulting Inc., Eli Lilly and Co., ICON PLC, IQVIA Holdings Inc., Laboratory Corp. of America Holdings, Medpace Holdings Inc., Novartis AG, Novo Nordisk AS, Parexel International Corp., Pfizer Inc., Sanofi SA, Syneos Health, Thermo Fisher Scientific Inc., and WuXi AppTec Co. Ltd. Also, the clinical trials market in the US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Executive Summary - Chart on Market Overview
Executive Summary - Data Table on Market Overview
Executive Summary - Chart on Country Market Characteristics
Executive Summary - Chart on Market Segmentation by Type
Executive Summary - Chart on Market Segmentation by Service Type
Executive Summary - Chart on Market Segmentation by Indication
Executive Summary - Chart on Company Market Positioning
2 Market Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
Overview on factors of disruption
2.4 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
3.1 Market ecosystem
Parent Market
Data Table on - Parent Market
3.2 Market characteristics
Market characteristics analysis
3.3 Value chain analysis
Value chain analysis
4 Market Sizing
4.1 Market definition
Offerings of companies included in the market definition
4.2 Market segment analysis
Market segments
4.3 Market size 2024
4.4 Market outlook: Forecast for 2024-2029
Chart on US - Market size and forecast 2024-2029 ($ billion)
Data Table on US - Market size and forecast 2024-2029 ($ billion)
Chart on US: Year-over-year growth 2024-2029 (%)
Data Table on US: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
5.1 Clinical Trials Market in US 2019 - 2023
Historic Market Size - Data Table on Clinical Trials Market in US 2019 - 2023 ($ billion)
5.2 Type segment analysis 2019 - 2023
Historic Market Size - Type Segment 2019 - 2023 ($ billion)
5.3 Service Type segment analysis 2019 - 2023
Historic Market Size - Service Type Segment 2019 - 2023 ($ billion)
5.4 Indication segment analysis 2019 - 2023
Historic Market Size - Indication Segment 2019 - 2023 ($ billion)
6 Qualitative Analysis
6.1 AI Impact on Clinical Trials Market in US
7 Five Forces Analysis
7.1 Five forces summary
Five forces analysis - Comparison between 2024 and 2029
7.2 Bargaining power of buyers
Bargaining power of buyers - Impact of key factors 2024 and 2029
7.3 Bargaining power of suppliers
Bargaining power of suppliers - Impact of key factors in 2024 and 2029
7.4 Threat of new entrants
Threat of new entrants - Impact of key factors in 2024 and 2029
7.5 Threat of substitutes
Threat of substitutes - Impact of key factors in 2024 and 2029
7.6 Threat of rivalry
Threat of rivalry - Impact of key factors in 2024 and 2029
7.7 Market condition
Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Type
8.1 Market segments
Chart on Type - Market share 2024-2029 (%)
Data Table on Type - Market share 2024-2029 (%)
8.2 Comparison by Type
Chart on Comparison by Type
Data Table on Comparison by Type
8.3 Phase III - Market size and forecast 2024-2029
Chart on Phase III - Market size and forecast 2024-2029 ($ billion)
Data Table on Phase III - Market size and forecast 2024-2029 ($ billion)
Chart on Phase III - Year-over-year growth 2024-2029 (%)
Data Table on Phase III - Year-over-year growth 2024-2029 (%)
8.4 Phase I - Market size and forecast 2024-2029
Chart on Phase I - Market size and forecast 2024-2029 ($ billion)
Data Table on Phase I - Market size and forecast 2024-2029 ($ billion)
Chart on Phase I - Year-over-year growth 2024-2029 (%)
Data Table on Phase I - Year-over-year growth 2024-2029 (%)
8.5 Phase II - Market size and forecast 2024-2029
Chart on Phase II - Market size and forecast 2024-2029 ($ billion)
Data Table on Phase II - Market size and forecast 2024-2029 ($ billion)
Chart on Phase II - Year-over-year growth 2024-2029 (%)
Data Table on Phase II - Year-over-year growth 2024-2029 (%)
8.6 Phase IV - Market size and forecast 2024-2029
Chart on Phase IV - Market size and forecast 2024-2029 ($ billion)
Data Table on Phase IV - Market size and forecast 2024-2029 ($ billion)
Chart on Phase IV - Year-over-year growth 2024-2029 (%)
Data Table on Phase IV - Year-over-year growth 2024-2029 (%)
8.7 Market opportunity by Type
Market opportunity by Type ($ billion)
Data Table on Market opportunity by Type ($ billion)
9 Market Segmentation by Service Type
9.1 Market segments
Chart on Service Type - Market share 2024-2029 (%)
Data Table on Service Type - Market share 2024-2029 (%)
9.2 Comparison by Service Type
Chart on Comparison by Service Type
Data Table on Comparison by Service Type
9.3 Interventional studies - Market size and forecast 2024-2029
Chart on Interventional studies - Market size and forecast 2024-2029 ($ billion)
Data Table on Interventional studies - Market size and forecast 2024-2029 ($ billion)
Chart on Interventional studies - Year-over-year growth 2024-2029 (%)
Data Table on Interventional studies - Year-over-year growth 2024-2029 (%)
9.4 Observational studies - Market size and forecast 2024-2029
Chart on Observational studies - Market size and forecast 2024-2029 ($ billion)
Data Table on Observational studies - Market size and forecast 2024-2029 ($ billion)
Chart on Observational studies - Year-over-year growth 2024-2029 (%)
Data Table on Observational studies - Year-over-year growth 2024-2029 (%)
9.5 Expanded access studies - Market size and forecast 2024-2029
Chart on Expanded access studies - Market size and forecast 2024-2029 ($ billion)
Data Table on Expanded access studies - Market size and forecast 2024-2029 ($ billion)
Chart on Expanded access studies - Year-over-year growth 2024-2029 (%)
Data Table on Expanded access studies - Year-over-year growth 2024-2029 (%)
9.6 Market opportunity by Service Type
Market opportunity by Service Type ($ billion)
Data Table on Market opportunity by Service Type ($ billion)
10 Market Segmentation by Indication
10.1 Market segments
Chart on Indication - Market share 2024-2029 (%)
Data Table on Indication - Market share 2024-2029 (%)
10.2 Comparison by Indication
Chart on Comparison by Indication
Data Table on Comparison by Indication
10.3 Oncology - Market size and forecast 2024-2029
Chart on Oncology - Market size and forecast 2024-2029 ($ billion)
Data Table on Oncology - Market size and forecast 2024-2029 ($ billion)
Chart on Oncology - Year-over-year growth 2024-2029 (%)
Data Table on Oncology - Year-over-year growth 2024-2029 (%)
10.4 CNS - Market size and forecast 2024-2029
Chart on CNS - Market size and forecast 2024-2029 ($ billion)
Data Table on CNS - Market size and forecast 2024-2029 ($ billion)
Chart on CNS - Year-over-year growth 2024-2029 (%)
Data Table on CNS - Year-over-year growth 2024-2029 (%)
10.5 Autoimmune/inflammation - Market size and forecast 2024-2029
Chart on Autoimmune/inflammation - Market size and forecast 2024-2029 ($ billion)
Data Table on Autoimmune/inflammation - Market size and forecast 2024-2029 ($ billion)
Chart on Autoimmune/inflammation - Year-over-year growth 2024-2029 (%)
Data Table on Autoimmune/inflammation - Year-over-year growth 2024-2029 (%)
10.6 Others - Market size and forecast 2024-2029
Chart on Others - Market size and forecast 2024-2029 ($ billion)
Data Table on Others - Market size and forecast 2024-2029 ($ billion)
Chart on Others - Year-over-year growth 2024-2029 (%)
Data Table on Others - Year-over-year growth 2024-2029 (%)
10.7 Market opportunity by Indication
Market opportunity by Indication ($ billion)
Data Table on Market opportunity by Indication ($ billion)
11 Customer Landscape
11.1 Customer landscape overview
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Drivers, Challenges, and Opportunity/Restraints
12.1 Market drivers
12.2 Market challenges
12.3 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
12.4 Market opportunities/restraints
13 Competitive Landscape
13.1 Overview
13.2 Competitive Landscape
Overview on criticality of inputs and factors of differentiation
13.3 Landscape disruption
Overview on factors of disruption
13.4 Industry risks
Impact of key risks on business
14 Competitive Analysis
14.1 Companies profiled
Companies covered
14.2 Company ranking index
Company ranking index
14.3 Market positioning of companies
Matrix on companies position and classification
14.4 Accell Clinical Research LLC
Accell Clinical Research LLC - Overview
Accell Clinical Research LLC - Product / Service
Accell Clinical Research LLC - Key offerings
SWOT
14.5 Caidya
Caidya - Overview
Caidya - Product / Service
Caidya - Key offerings
SWOT
14.6 Charles River Laboratories International Inc.
Charles River Laboratories International Inc. - Overview
Charles River Laboratories International Inc. - Business segments
Charles River Laboratories International Inc. - Key offerings
Charles River Laboratories International Inc. - Segment focus
SWOT
14.7 Clinipace Inc.
Clinipace Inc. - Overview
Clinipace Inc. - Product / Service
Clinipace Inc. - Key offerings
SWOT
14.8 CTI Clinical Trial and Consulting Inc.
CTI Clinical Trial and Consulting Inc. - Overview
CTI Clinical Trial and Consulting Inc. - Product / Service
CTI Clinical Trial and Consulting Inc. - Key offerings
SWOT
14.9 Eli Lilly and Co.
Eli Lilly and Co. - Overview
Eli Lilly and Co. - Product / Service
Eli Lilly and Co. - Key offerings
SWOT
14.10 ICON plc
ICON plc - Overview
ICON plc - Product / Service
ICON plc - Key offerings
SWOT
14.11 IQVIA Holdings Inc.
IQVIA Holdings Inc. - Overview
IQVIA Holdings Inc. - Business segments
IQVIA Holdings Inc. - Key offerings
IQVIA Holdings Inc. - Segment focus
SWOT
14.12 Laboratory Corp. of America Holdings
Laboratory Corp. of America Holdings - Overview
Laboratory Corp. of America Holdings - Business segments
Laboratory Corp. of America Holdings - Key news
Laboratory Corp. of America Holdings - Key offerings
Laboratory Corp. of America Holdings - Segment focus
SWOT
14.13 Medpace Holdings Inc.
Medpace Holdings Inc. - Overview
Medpace Holdings Inc. - Product / Service
Medpace Holdings Inc. - Key offerings
SWOT
14.14 Parexel International Corp.
Parexel International Corp. - Overview
Parexel International Corp. - Product / Service
Parexel International Corp. - Key offerings
SWOT
14.15 Pfizer Inc.
Pfizer Inc. - Overview
Pfizer Inc. - Product / Service
Pfizer Inc. - Key news
Pfizer Inc. - Key offerings
SWOT
14.16 Sanofi SA
Sanofi SA - Overview
Sanofi SA - Business segments
Sanofi SA - Key news
Sanofi SA - Key offerings
Sanofi SA - Segment focus
SWOT
14.17 Syneos Health
Syneos Health - Overview
Syneos Health - Product / Service
Syneos Health - Key offerings
SWOT
14.18 Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. - Overview
Thermo Fisher Scientific Inc. - Business segments
Thermo Fisher Scientific Inc. - Key news
Thermo Fisher Scientific Inc. - Key offerings
Thermo Fisher Scientific Inc. - Segment focus
SWOT
15 Appendix
15.1 Scope of the report
15.2 Inclusions and exclusions checklist
Inclusions checklist
Exclusions checklist
15.3 Currency conversion rates for US$
Currency conversion rates for US$
15.4 Research methodology
Research methodology
15.5 Data procurement
Information sources
15.6 Data validation
Data validation
15.7 Validation techniques employed for market sizing
Validation techniques employed for market sizing
15.8 Data synthesis
Data synthesis
15.9 360 degree market analysis
360 degree market analysis
15.10 List of abbreviations
List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Country Market Characteristics
Exhibits 4: Executive Summary - Chart on Market Segmentation by Type
Exhibits 5: Executive Summary - Chart on Market Segmentation by Service Type
Exhibits 6: Executive Summary - Chart on Market Segmentation by Indication
Exhibits 7: Executive Summary - Chart on Company Market Positioning
Exhibits 8: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 9: Overview on criticality of inputs and factors of differentiation
Exhibits 10: Overview on factors of disruption
Exhibits 11: Impact of drivers and challenges in 2024 and 2029
Exhibits 12: Parent Market
Exhibits 13: Data Table on - Parent Market
Exhibits 14: Market characteristics analysis
Exhibits 15: Value chain analysis
Exhibits 16: Offerings of companies included in the market definition
Exhibits 17: Market segments
Exhibits 18: Chart on US - Market size and forecast 2024-2029 ($ billion)
Exhibits 19: Data Table on US - Market size and forecast 2024-2029 ($ billion)
Exhibits 20: Chart on US: Year-over-year growth 2024-2029 (%)
Exhibits 21: Data Table on US: Year-over-year growth 2024-2029 (%)
Exhibits 22: Historic Market Size - Data Table on Clinical Trials Market in US 2019 - 2023 ($ billion)
Exhibits 23: Historic Market Size - Type Segment 2019 - 2023 ($ billion)
Exhibits 24: Historic Market Size - Service Type Segment 2019 - 2023 ($ billion)
Exhibits 25: Historic Market Size - Indication Segment 2019 - 2023 ($ billion)
Exhibits 26: Five forces analysis - Comparison between 2024 and 2029
Exhibits 27: Bargaining power of buyers - Impact of key factors 2024 and 2029
Exhibits 28: Bargaining power of suppliers - Impact of key factors in 2024 and 2029
Exhibits 29: Threat of new entrants - Impact of key factors in 2024 and 2029
Exhibits 30: Threat of substitutes - Impact of key factors in 2024 and 2029
Exhibits 31: Threat of rivalry - Impact of key factors in 2024 and 2029
Exhibits 32: Chart on Market condition - Five forces 2024 and 2029
Exhibits 33: Chart on Type - Market share 2024-2029 (%)
Exhibits 34: Data Table on Type - Market share 2024-2029 (%)
Exhibits 35: Chart on Comparison by Type
Exhibits 36: Data Table on Comparison by Type
Exhibits 37: Chart on Phase III - Market size and forecast 2024-2029 ($ billion)
Exhibits 38: Data Table on Phase III - Market size and forecast 2024-2029 ($ billion)
Exhibits 39: Chart on Phase III - Year-over-year growth 2024-2029 (%)
Exhibits 40: Data Table on Phase III - Year-over-year growth 2024-2029 (%)
Exhibits 41: Chart on Phase I - Market size and forecast 2024-2029 ($ billion)
Exhibits 42: Data Table on Phase I - Market size and forecast 2024-2029 ($ billion)
Exhibits 43: Chart on Phase I - Year-over-year growth 2024-2029 (%)
Exhibits 44: Data Table on Phase I - Year-over-year growth 2024-2029 (%)
Exhibits 45: Chart on Phase II - Market size and forecast 2024-2029 ($ billion)
Exhibits 46: Data Table on Phase II - Market size and forecast 2024-2029 ($ billion)
Exhibits 47: Chart on Phase II - Year-over-year growth 2024-2029 (%)
Exhibits 48: Data Table on Phase II - Year-over-year growth 2024-2029 (%)
Exhibits 49: Chart on Phase IV - Market size and forecast 2024-2029 ($ billion)
Exhibits 50: Data Table on Phase IV - Market size and forecast 2024-2029 ($ billion)
Exhibits 51: Chart on Phase IV - Year-over-year growth 2024-2029 (%)
Exhibits 52: Data Table on Phase IV - Year-over-year growth 2024-2029 (%)
Exhibits 53: Market opportunity by Type ($ billion)
Exhibits 54: Data Table on Market opportunity by Type ($ billion)
Exhibits 55: Chart on Service Type - Market share 2024-2029 (%)
Exhibits 56: Data Table on Service Type - Market share 2024-2029 (%)
Exhibits 57: Chart on Comparison by Service Type
Exhibits 58: Data Table on Comparison by Service Type
Exhibits 59: Chart on Interventional studies - Market size and forecast 2024-2029 ($ billion)
Exhibits 60: Data Table on Interventional studies - Market size and forecast 2024-2029 ($ billion)
Exhibits 61: Chart on Interventional studies - Year-over-year growth 2024-2029 (%)
Exhibits 62: Data Table on Interventional studies - Year-over-year growth 2024-2029 (%)
Exhibits 63: Chart on Observational studies - Market size and forecast 2024-2029 ($ billion)
Exhibits 64: Data Table on Observational studies - Market size and forecast 2024-2029 ($ billion)
Exhibits 65: Chart on Observational studies - Year-over-year growth 2024-2029 (%)
Exhibits 66: Data Table on Observational studies - Year-over-year growth 2024-2029 (%)
Exhibits 67: Chart on Expanded access studies - Market size and forecast 2024-2029 ($ billion)
Exhibits 68: Data Table on Expanded access studies - Market size and forecast 2024-2029 ($ billion)
Exhibits 69: Chart on Expanded access studies - Year-over-year growth 2024-2029 (%)
Exhibits 70: Data Table on Expanded access studies - Year-over-year growth 2024-2029 (%)
Exhibits 71: Market opportunity by Service Type ($ billion)
Exhibits 72: Data Table on Market opportunity by Service Type ($ billion)
Exhibits 73: Chart on Indication - Market share 2024-2029 (%)
Exhibits 74: Data Table on Indication - Market share 2024-2029 (%)
Exhibits 75: Chart on Comparison by Indication
Exhibits 76: Data Table on Comparison by Indication
Exhibits 77: Chart on Oncology - Market size and forecast 2024-2029 ($ billion)
Exhibits 78: Data Table on Oncology - Market size and forecast 2024-2029 ($ billion)
Exhibits 79: Chart on Oncology - Year-over-year growth 2024-2029 (%)
Exhibits 80: Data Table on Oncology - Year-over-year growth 2024-2029 (%)
Exhibits 81: Chart on CNS - Market size and forecast 2024-2029 ($ billion)
Exhibits 82: Data Table on CNS - Market size and forecast 2024-2029 ($ billion)
Exhibits 83: Chart on CNS - Year-over-year growth 2024-2029 (%)
Exhibits 84: Data Table on CNS - Year-over-year growth 2024-2029 (%)
Exhibits 85: Chart on Autoimmune/inflammation - Market size and forecast 2024-2029 ($ billion)
Exhibits 86: Data Table on Autoimmune/inflammation - Market size and forecast 2024-2029 ($ billion)
Exhibits 87: Chart on Autoimmune/inflammation - Year-over-year growth 2024-2029 (%)
Exhibits 88: Data Table on Autoimmune/inflammation - Year-over-year growth 2024-2029 (%)
Exhibits 89: Chart on Others - Market size and forecast 2024-2029 ($ billion)
Exhibits 90: Data Table on Others - Market size and forecast 2024-2029 ($ billion)
Exhibits 91: Chart on Others - Year-over-year growth 2024-2029 (%)
Exhibits 92: Data Table on Others - Year-over-year growth 2024-2029 (%)
Exhibits 93: Market opportunity by Indication ($ billion)
Exhibits 94: Data Table on Market opportunity by Indication ($ billion)
Exhibits 95: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 96: Impact of drivers and challenges in 2024 and 2029
Exhibits 97: Overview on criticality of inputs and factors of differentiation
Exhibits 98: Overview on factors of disruption
Exhibits 99: Impact of key risks on business
Exhibits 100: Companies covered
Exhibits 101: Company ranking index
Exhibits 102: Matrix on companies position and classification
Exhibits 103: Accell Clinical Research LLC - Overview
Exhibits 104: Accell Clinical Research LLC - Product / Service
Exhibits 105: Accell Clinical Research LLC - Key offerings
Exhibits 106: SWOT
Exhibits 107: Caidya - Overview
Exhibits 108: Caidya - Product / Service
Exhibits 109: Caidya - Key offerings
Exhibits 110: SWOT
Exhibits 111: Charles River Laboratories International Inc. - Overview
Exhibits 112: Charles River Laboratories International Inc. - Business segments
Exhibits 113: Charles River Laboratories International Inc. - Key offerings
Exhibits 114: Charles River Laboratories International Inc. - Segment focus
Exhibits 115: SWOT
Exhibits 116: Clinipace Inc. - Overview
Exhibits 117: Clinipace Inc. - Product / Service
Exhibits 118: Clinipace Inc. - Key offerings
Exhibits 119: SWOT
Exhibits 120: CTI Clinical Trial and Consulting Inc. - Overview
Exhibits 121: CTI Clinical Trial and Consulting Inc. - Product / Service
Exhibits 122: CTI Clinical Trial and Consulting Inc. - Key offerings
Exhibits 123: SWOT
Exhibits 124: Eli Lilly and Co. - Overview
Exhibits 125: Eli Lilly and Co. - Product / Service
Exhibits 126: Eli Lilly and Co. - Key offerings
Exhibits 127: SWOT
Exhibits 128: ICON plc - Overview
Exhibits 129: ICON plc - Product / Service
Exhibits 130: ICON plc - Key offerings
Exhibits 131: SWOT
Exhibits 132: IQVIA Holdings Inc. - Overview
Exhibits 133: IQVIA Holdings Inc. - Business segments
Exhibits 134: IQVIA Holdings Inc. - Key offerings
Exhibits 135: IQVIA Holdings Inc. - Segment focus
Exhibits 136: SWOT
Exhibits 137: Laboratory Corp. of America Holdings - Overview
Exhibits 138: Laboratory Corp. of America Holdings - Business segments
Exhibits 139: Laboratory Corp. of America Holdings - Key news
Exhibits 140: Laboratory Corp. of America Holdings - Key offerings
Exhibits 141: Laboratory Corp. of America Holdings - Segment focus
Exhibits 142: SWOT
Exhibits 143: Medpace Holdings Inc. - Overview
Exhibits 144: Medpace Holdings Inc. - Product / Service
Exhibits 145: Medpace Holdings Inc. - Key offerings
Exhibits 146: SWOT
Exhibits 147: Parexel International Corp. - Overview
Exhibits 148: Parexel International Corp. - Product / Service
Exhibits 149: Parexel International Corp. - Key offerings
Exhibits 150: SWOT
Exhibits 151: Pfizer Inc. - Overview
Exhibits 152: Pfizer Inc. - Product / Service
Exhibits 153: Pfizer Inc. - Key news
Exhibits 154: Pfizer Inc. - Key offerings
Exhibits 155: SWOT
Exhibits 156: Sanofi SA - Overview
Exhibits 157: Sanofi SA - Business segments
Exhibits 158: Sanofi SA - Key news
Exhibits 159: Sanofi SA - Key offerings
Exhibits 160: Sanofi SA - Segment focus
Exhibits 161: SWOT
Exhibits 162: Syneos Health - Overview
Exhibits 163: Syneos Health - Product / Service
Exhibits 164: Syneos Health - Key offerings
Exhibits 165: SWOT
Exhibits 166: Thermo Fisher Scientific Inc. - Overview
Exhibits 167: Thermo Fisher Scientific Inc. - Business segments
Exhibits 168: Thermo Fisher Scientific Inc. - Key news
Exhibits 169: Thermo Fisher Scientific Inc. - Key offerings
Exhibits 170: Thermo Fisher Scientific Inc. - Segment focus
Exhibits 171: SWOT
Exhibits 172: Inclusions checklist
Exhibits 173: Exclusions checklist
Exhibits 174: Currency conversion rates for US$
Exhibits 175: Research methodology
Exhibits 176: Information sources
Exhibits 177: Data validation
Exhibits 178: Validation techniques employed for market sizing
Exhibits 179: Data synthesis
Exhibits 180: 360 degree market analysis
Exhibits 181: List of abbreviations

Executive Summary

The following companies are recognized as the key players in the clinical trials market in us: Accell Clinical Research LLC, Apex Medical Research Inc., Caidya, Charles River Laboratories International Inc., Clario, Clinipace Inc., CTI Clinical Trial and Consulting Inc., Eli Lilly and Co., ICON plc, IQVIA Holdings Inc., Laboratory Corp. of America Holdings, Medpace Holdings Inc., Novartis AG, Novo Nordisk AS, Parexel International Corp., Pfizer Inc., Sanofi SA, Syneos Health, Thermo Fisher Scientific Inc., and WuXi AppTec Co. Ltd..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is advancement in technology and scientific research."

According to the report, one of the major drivers for this market is the rise in number of clinical trials of drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Accell Clinical Research LLC
  • Apex Medical Research Inc.
  • Caidya
  • Charles River Laboratories International Inc.
  • Clario
  • Clinipace Inc.
  • CTI Clinical Trial and Consulting Inc.
  • Eli Lilly and Co.
  • ICON plc
  • IQVIA Holdings Inc.
  • Laboratory Corp. of America Holdings
  • Medpace Holdings Inc.
  • Novartis AG
  • Novo Nordisk AS
  • Parexel International Corp.
  • Pfizer Inc.
  • Sanofi SA
  • Syneos Health
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co. Ltd.